Q3 2021 Investor Relations Results

Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials Neuroscience Ophthalmology Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health Abbreviations CRM IHD icenticaftor - CFTR potentiator Study Indication Phase Patients Primary Outcome Measures Arms Intervention NCT04072887 (CQBW251B2201) Chronic obstructive pulmonary disease (COPD) Phase 2 956 Trough FEV1 (Forced Expiratory Volume in 1 second) change from baseline after 12 weeks of treatment QBW251 450 mg QBW251 300 mg QBW251 150 mg QBW251 75 mg QBW251 25 mg Placebo COPD patients on background triple inhaled therapy (LABA / LAMA / ICS) Target Patients Read-out Milesstone(s) Publication 2022 Primary publications planned for 2022 103 Investor Relations | Q3 2021 Results NOVARTIS | Reimagining Medicine

View entire presentation